Novel oral drug improves sunlight tolerance in patients with erythropoietic protoporphyria
Dersimelagon increases cutaneous melanin density.
Related Articles
4 Years In, a Sobering Look at Long COVID Progress
Long COVID is still a disease diagnosed by figuring out what a patient does not have. Symptom management is the only treatment now.
Impact of Ketogenic and Low-Glycemic Diets on Inflammatory Skin Conditions
Diet plays an emerging role in dermatologic therapy. The ketogenic and low-glycemic diets have potential anti-inflammatory and metabolic effects, making them attractive for treating inflammatory…
Meta-analysis Identifies Atopic Dermatitis as Potential Risk Factor for Headache Disorder or Migraine
Key clinical point: Atopic dermatitis (AD) is significantly associated with a higher ri
IV Ketamine Promising for Severe Refractory Headache in Children
Overall, the treatment was “safe and well tolerated.”
Empowering ICU physicians in MCS critical care
Fellowship programs can aid in training cardiogenic shock.
What’s Driving the Higher Breast Cancer Death Rate in Black Women?
New research suggests that racial disparities in breast cancer are driven by more than socioeconomic factors.
Eradicating uncertainty: A review of Pseudomonas aeruginosa eradication in bronchiectasis
Ideal treatment to eliminate NCFB is unknown, though studies have pointed to inhaled tobramycin for chronic P. aeruginosa infections.
Ultraprocessed Food May Increase Long-Term Risk for IBS
Diets with large amounts of ultraprocessed food may up the risk of developing IBS by 20%, study finds.
Chronic Pain Linked to Accelerated Brain Aging
The acceleration in brain aging was largely driven by the hippocampus and predicted memory decline and incident dementia during follow-up.